EP1423144A4 - Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease - Google Patents

Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease

Info

Publication number
EP1423144A4
EP1423144A4 EP02753530A EP02753530A EP1423144A4 EP 1423144 A4 EP1423144 A4 EP 1423144A4 EP 02753530 A EP02753530 A EP 02753530A EP 02753530 A EP02753530 A EP 02753530A EP 1423144 A4 EP1423144 A4 EP 1423144A4
Authority
EP
European Patent Office
Prior art keywords
cd40r
alzheimer
disruption
disease
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02753530A
Other languages
German (de)
French (fr)
Other versions
EP1423144A2 (en
Inventor
Jun Tan
Terrence C Town
Michael Mullan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roskamp Research LLC
Original Assignee
University of South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida filed Critical University of South Florida
Priority claimed from PCT/US2002/027035 external-priority patent/WO2003014328A2/en
Publication of EP1423144A2 publication Critical patent/EP1423144A2/en
Publication of EP1423144A4 publication Critical patent/EP1423144A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/525Tumor necrosis factor [TNF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP02753530A 2001-08-10 2002-08-12 Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease Withdrawn EP1423144A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31111501P 2001-08-10 2001-08-10
US311115P 2001-08-10
PCT/US2002/027035 WO2003014328A2 (en) 1999-06-01 2002-08-12 Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
EP1423144A2 EP1423144A2 (en) 2004-06-02
EP1423144A4 true EP1423144A4 (en) 2006-08-02

Family

ID=32298094

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02753530A Withdrawn EP1423144A4 (en) 2001-08-10 2002-08-12 Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease

Country Status (3)

Country Link
EP (1) EP1423144A4 (en)
AU (1) AU2002313811A1 (en)
CA (1) CA2467919A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023590A2 (en) * 1998-10-20 2000-04-27 Georgetown University Medical Center INHIBITION OF CD40-MEDIATED NFλB ACTIVATION
WO2001096397A2 (en) * 2000-06-09 2001-12-20 Biogen, Inc. Cd154 variants and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023590A2 (en) * 1998-10-20 2000-04-27 Georgetown University Medical Center INHIBITION OF CD40-MEDIATED NFλB ACTIVATION
WO2001096397A2 (en) * 2000-06-09 2001-12-20 Biogen, Inc. Cd154 variants and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STUBER ECKHARD ET AL: "Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion", BIOSIS, 1996, XP002189392 *

Also Published As

Publication number Publication date
CA2467919A1 (en) 2003-02-20
EP1423144A2 (en) 2004-06-02
AU2002313811A1 (en) 2003-02-24

Similar Documents

Publication Publication Date Title
AU2003284968A8 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
AU2001233299A1 (en) Methods for treating alzheimer's disease
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
EP1416961A4 (en) Composition and method for the treatment of disease
AU2002306848A1 (en) Methods of treating alzheimer's disease with piperidin derivates
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
AU2003220096A8 (en) Methods for alzheimer's disease treatment and cognitive enhancement
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU2003209301A8 (en) Treatments for neurotoxicity in alzheimer's disease
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
EP1364648A4 (en) Cryptotanshinone for preventing and alleviating alzheimer's disease
IL172213A0 (en) Compounds useful in the therapy of alzheimer's disease and formulations containing them
AU2003248660A8 (en) Treatment of vascular dysfunction and alzheimer's disease
EP1181550A4 (en) Methods for the identification of compounds for the treatment of alzheimer's disease
GB0011408D0 (en) Therapeutic combination for treating Alzheimer's Disease
PL377110A1 (en) Prevention and treatment of alzheimer's disease
EP1423144A4 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
AU2003230848A8 (en) Methods and compositions for treating alzheimer's disease
AU2003286530A8 (en) Substituted peptides useful in the treatment of alzheimer's disease
AUPR227000A0 (en) Agents for the treatment of alzheimer's disease and screening and methods for the same
AU2002324446A1 (en) Substituted aminoalcohols useful in treatment of alzheimer's disease
AU2002316622A1 (en) Aminediols for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040309

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060705

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20060629BHEP

Ipc: G01N 33/50 20060101ALI20060629BHEP

Ipc: A61K 39/00 20060101ALI20060629BHEP

Ipc: A61K 38/00 20060101AFI20060629BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROSKAMP RESEARCH LLC

17Q First examination report despatched

Effective date: 20080303

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100302